Please assess the completion status of the following clinical trial:

Trial Title: iHIVARNA Clinical Trial in HIV Infected Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 18 years of age;~2. Voluntarily signed informed consent;~3. Proven HIV-1 infection (with documented antibodies against HIV-1 and a detectable plasma HIV-1 RNA before initiation of therapy);~4. On stable treatment with cART regimen (antiretroviral therapy consisting of at least three registered antiretroviral agents) for at least 3 years;~5. Nadir CD4+ ≥ 350 cells/μl (up to 2 occasional determinations ≤ 350 cells/μl are allowed);~6. Current CD4+ cell count ≥ 450 cells/μl;~7. HIV-RNA below 50 copies/mL in the last 6 months prior to randomization, during at least two measurements (occasional so called 'blips' ≤ 500 copies/mL are permitted);~8. If sexually active, willing to use a reliable method of reducing the risk of transmission to their sexual partners during treatment interruption (including PrEP).~   1. For heterosexually active female, using an effective method of contraception with partner (combined oral contraceptive pill; injectable or implanted contraceptive; IUD/IUS; consistent record with condoms; physiological or anatomical sterility (in self or partner) from 14 days prior to the first vaccination until 4 months after the last vaccination.~For heterosexually active male, using an effective method of contraception with their partner from the first day of vaccination until 4 months after the last vaccination. -~Exclusion Criteria:~1. Treatment with non-cART regimen prior to cART regimen;~2. Previous failure to antiretroviral and/or mutations conferring genotypic resistance to antiretroviral therapy;~3. Non-subtype B HIV infection;~4. Active Hepatitis B virus and/or Hepatitis C virus co-infection;~5. History of a CDC class C event (see appendix A);~6. Pregnant female (screened with a positive pregnancy test), lactating or intending to become pregnant during the study;~7. Active malignancy ≤ 30 days (extended period on the clinical assessment of the investigator) prior to screening;~8. Active infection with fever (38°C or above) ≤ 10 days of screening and/or first vaccination;~9. Therapy with immunomodulatory agents (e.g. systemic corticosteroids), including cytokines (e.g. IL-2), immunoglobulins and/or cytostatic chemotherapy ≤ 90 days prior to screening. This does not include seasonal influenza, hepatitis B and/or other travel related vaccines;~10. Congenital, acquired or induced coagulation disorders, such as thrombocytopenia (thrombocytes \< 150x109/L) and/or current use of anti-coagulant medication (e.g. coumarins, inhibitors of Xa); Usage of NSAIDs (including acetylsalicylic acid) is allowed, however it is advised to interrupt therapy 10 days ahead of vaccination;~11. Usage of any investigational drug ≤ 90 days prior to study entry;~12. An employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, or is a family member of an employee or the investigator Any other condition, which, in the opinion of the investigator, may interfere with the evaluation of the study objectives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- iHIVARNA-01 (Type: EXPERIMENTAL): Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
- TriMix (Type: ACTIVE_COMPARATOR): Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
- Placebo (Type: PLACEBO_COMPARATOR): Water for injection 3 vaccinations, two weeks interval

Based on this trial design, predict the completion outcome and termination type (if applicable).